Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311442935> ?p ?o ?g. }
- W4311442935 endingPage "208" @default.
- W4311442935 startingPage "195" @default.
- W4311442935 abstract "Pimavanserin is approved in the USA to treat hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). We evaluated mortality in patients with PDP after initiation of pimavanserin or comparator atypical antipsychotics, overall, over time, and across subgroups. A cohort of patients aged ≥65 years in the USA with PDP newly initiating pimavanserin or a comparator atypical antipsychotic (clozapine, quetiapine, risperidone, olanzapine, aripiprazole, brexpiprazole) was identified in 2016–2019 Medicare claims data. All-cause mortality in the propensity score–matched treatment groups was compared with hazard ratios (HRs) and 95% confidence intervals (CIs) estimated with Cox-proportional hazards models. Cumulative incidence curves and time period–specific models evaluated risk over time. Subgroup and sensitivity analyses were performed, including a sub-cohort of long-term care (LTC) or skilled nursing facility (SNF) residents. We identified 2892 pimavanserin initiators and 19,083 comparator initiators (overall 47% female, mean age = 80.9 years, LTC/SNF residents = 30%). Before matching, pimavanserin users had fewer severe comorbidities and more anti-Parkinson medication use than comparators. Matching resulted in 2891 patients in both groups, and all covariates were well balanced. In the matched cohort, the HR for mortality for pimavanserin versus comparator was 0.78 (95% CI 0.67–0.91), with the lowest time period–specific HRs in the first 180 days. Hazard ratios were similar across sensitivity analyses and subgroups. In LTC/SNF residents, the HR was 0.78 (95% CI 0.60–1.01). The observed mortality rates were lower among patients treated with pimavanserin compared with those treated with other atypical antipsychotics. European Union Post-authorization Study (EU PAS) register number 46331." @default.
- W4311442935 created "2022-12-26" @default.
- W4311442935 creator A5001638414 @default.
- W4311442935 creator A5028799962 @default.
- W4311442935 creator A5030831140 @default.
- W4311442935 creator A5032608817 @default.
- W4311442935 creator A5044909684 @default.
- W4311442935 creator A5047851852 @default.
- W4311442935 creator A5087459523 @default.
- W4311442935 date "2022-12-14" @default.
- W4311442935 modified "2023-10-10" @default.
- W4311442935 title "Mortality in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study" @default.
- W4311442935 cites W1783351295 @default.
- W4311442935 cites W1849521086 @default.
- W4311442935 cites W2000991311 @default.
- W4311442935 cites W2013178525 @default.
- W4311442935 cites W2014415089 @default.
- W4311442935 cites W2049953117 @default.
- W4311442935 cites W2059992689 @default.
- W4311442935 cites W2067995563 @default.
- W4311442935 cites W2107881620 @default.
- W4311442935 cites W2111635289 @default.
- W4311442935 cites W2117979215 @default.
- W4311442935 cites W2126049444 @default.
- W4311442935 cites W2142509258 @default.
- W4311442935 cites W2147295413 @default.
- W4311442935 cites W2153641048 @default.
- W4311442935 cites W2169008240 @default.
- W4311442935 cites W2409959512 @default.
- W4311442935 cites W2478394792 @default.
- W4311442935 cites W2516683410 @default.
- W4311442935 cites W2571002748 @default.
- W4311442935 cites W2735301415 @default.
- W4311442935 cites W2748586861 @default.
- W4311442935 cites W2751630686 @default.
- W4311442935 cites W2769541324 @default.
- W4311442935 cites W2786890905 @default.
- W4311442935 cites W2939246364 @default.
- W4311442935 cites W2969846169 @default.
- W4311442935 cites W2981445184 @default.
- W4311442935 cites W3121862538 @default.
- W4311442935 cites W3138193833 @default.
- W4311442935 cites W3173858109 @default.
- W4311442935 cites W3188114504 @default.
- W4311442935 cites W3192771368 @default.
- W4311442935 cites W3210039537 @default.
- W4311442935 cites W4282958777 @default.
- W4311442935 cites W568113025 @default.
- W4311442935 doi "https://doi.org/10.1007/s40264-022-01260-6" @default.
- W4311442935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36517664" @default.
- W4311442935 hasPublicationYear "2022" @default.
- W4311442935 type Work @default.
- W4311442935 citedByCount "5" @default.
- W4311442935 countsByYear W43114429352023 @default.
- W4311442935 crossrefType "journal-article" @default.
- W4311442935 hasAuthorship W4311442935A5001638414 @default.
- W4311442935 hasAuthorship W4311442935A5028799962 @default.
- W4311442935 hasAuthorship W4311442935A5030831140 @default.
- W4311442935 hasAuthorship W4311442935A5032608817 @default.
- W4311442935 hasAuthorship W4311442935A5044909684 @default.
- W4311442935 hasAuthorship W4311442935A5047851852 @default.
- W4311442935 hasAuthorship W4311442935A5087459523 @default.
- W4311442935 hasBestOaLocation W43114429351 @default.
- W4311442935 hasConcept C118552586 @default.
- W4311442935 hasConcept C126322002 @default.
- W4311442935 hasConcept C17923572 @default.
- W4311442935 hasConcept C201903717 @default.
- W4311442935 hasConcept C207103383 @default.
- W4311442935 hasConcept C2776412080 @default.
- W4311442935 hasConcept C2776619155 @default.
- W4311442935 hasConcept C2779727114 @default.
- W4311442935 hasConcept C2780057945 @default.
- W4311442935 hasConcept C2780211496 @default.
- W4311442935 hasConcept C2780494398 @default.
- W4311442935 hasConcept C2780634440 @default.
- W4311442935 hasConcept C2780864610 @default.
- W4311442935 hasConcept C44249647 @default.
- W4311442935 hasConcept C50382708 @default.
- W4311442935 hasConcept C71924100 @default.
- W4311442935 hasConcept C72563966 @default.
- W4311442935 hasConcept C88879693 @default.
- W4311442935 hasConceptScore W4311442935C118552586 @default.
- W4311442935 hasConceptScore W4311442935C126322002 @default.
- W4311442935 hasConceptScore W4311442935C17923572 @default.
- W4311442935 hasConceptScore W4311442935C201903717 @default.
- W4311442935 hasConceptScore W4311442935C207103383 @default.
- W4311442935 hasConceptScore W4311442935C2776412080 @default.
- W4311442935 hasConceptScore W4311442935C2776619155 @default.
- W4311442935 hasConceptScore W4311442935C2779727114 @default.
- W4311442935 hasConceptScore W4311442935C2780057945 @default.
- W4311442935 hasConceptScore W4311442935C2780211496 @default.
- W4311442935 hasConceptScore W4311442935C2780494398 @default.
- W4311442935 hasConceptScore W4311442935C2780634440 @default.
- W4311442935 hasConceptScore W4311442935C2780864610 @default.
- W4311442935 hasConceptScore W4311442935C44249647 @default.
- W4311442935 hasConceptScore W4311442935C50382708 @default.
- W4311442935 hasConceptScore W4311442935C71924100 @default.
- W4311442935 hasConceptScore W4311442935C72563966 @default.